Log in
NASDAQ:SLRX

Salarius Pharmaceuticals Stock Forecast, Price & News

$0.79
+0.01 (+1.28 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.75
Now: $0.79
$0.83
50-Day Range
$0.77
MA: $0.84
$0.92
52-Week Range
$0.56
Now: $0.79
$5.35
Volume163,900 shs
Average Volume397,597 shs
Market Capitalization$15.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.07 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLRX
CUSIPN/A
CIKN/A
Phone832-834-6992
Employees7

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.46 million
Book Value$2.35 per share

Profitability

Net Income$-6,940,000.00
Net Margins-195.34%

Miscellaneous

Market Cap$15.66 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$0.79
+0.01 (+1.28 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Salarius Pharmaceuticals (NASDAQ:SLRX) Frequently Asked Questions

How has Salarius Pharmaceuticals' stock been impacted by COVID-19?

Salarius Pharmaceuticals' stock was trading at $0.7201 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SLRX stock has increased by 9.7% and is now trading at $0.79.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Salarius Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Salarius Pharmaceuticals
.

When is Salarius Pharmaceuticals' next earnings date?

Salarius Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Salarius Pharmaceuticals
.

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) issued its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.03. The business earned $1.24 million during the quarter. Salarius Pharmaceuticals had a negative net margin of 195.34% and a negative return on equity of 68.95%.
View Salarius Pharmaceuticals' earnings history
.

What price target have analysts set for SLRX?

2 analysts have issued twelve-month price objectives for Salarius Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Salarius Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 532.9% from the stock's current price.
View analysts' price targets for Salarius Pharmaceuticals
.

Are investors shorting Salarius Pharmaceuticals?

Salarius Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 675,900 shares, an increase of 22.6% from the September 15th total of 551,100 shares. Based on an average daily trading volume, of 234,300 shares, the short-interest ratio is currently 2.9 days.
View Salarius Pharmaceuticals' Short Interest
.

Who are some of Salarius Pharmaceuticals' key competitors?

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).

Who are Salarius Pharmaceuticals' key executives?

Salarius Pharmaceuticals' management team includes the following people:
  • Mr. David J. Arthur M.B.A., CEO, Pres & Director (Age 57, Pay $325.5k)
  • Mr. Mark J. Rosenblum, Exec. VP of Fin. & CFO (Age 67, Pay $499.44k)
  • Dr. Bruce J. McCreedy Jr., Interim Chief Scientific Officer & Independent Director (Age 61, Pay $23.75k)
  • Dr. Nadeem Q. Mirza M.D., M.P.H., Sr. VP of Clinical Devel.
  • Dr. Daniela Y. Santiesteban, Director of Research and Bus. Devel.

What is Salarius Pharmaceuticals' stock symbol?

Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLRX."

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Salarius Pharmaceuticals' stock price today?

One share of SLRX stock can currently be purchased for approximately $0.79.

How big of a company is Salarius Pharmaceuticals?

Salarius Pharmaceuticals has a market capitalization of $15.66 million and generates $3.46 million in revenue each year. The company earns $-6,940,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Salarius Pharmaceuticals employs 7 workers across the globe.

What is Salarius Pharmaceuticals' official website?

The official website for Salarius Pharmaceuticals is www.salariuspharma.com.

How can I contact Salarius Pharmaceuticals?

Salarius Pharmaceuticals' mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The company can be reached via phone at 832-834-6992 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.